StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note published on Tuesday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Ayala Pharmaceuticals stock opened at $0.03 on Tuesday. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49. The company has a market capitalization of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.81. The business’s fifty day simple moving average is $0.05 and its two-hundred day simple moving average is $0.11.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.